BPIQ Blog

Dec 9, 20193 min read

Merck acuires Arqule: Non-covalent Btk kinase inhibitors take center stage

Merck (MRK.N) reported today that it is buying ARQL for over a 100% premium from Friday's closing price (https://reut.rs/341eQv1). This...

Jun 14, 20192 min read

ARQL 531 - Blood Cancer Promise and Fuel for ARQL Investors

Congrats to ARQL and especially CLL (a type of blood cancer) patients on the impressive early-stage data presented today at a poster...

Mar 8, 20193 min read

ARQL Surprises Investors with Clinical Trial Updates

ARQL pleasantly surprised investors yesterday on its quarterly call by giving two positive clinical trial updates. First, and most...

Jump start your biotech due diligence

Our platform helps you uncover your next biotech investment opportunity